Payment overview · 2025
General Payments
$5,216.14
73 reported records · 20 companies
Healthcare provider profile · identity verified
Joseph Degregorio, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · GLEN RIDGE, NJ · NPI 1023086691
Verified facts
What the public records show
CMS Open Payments records show Joseph Degregorio, MD received $5,216.14 in general payments during 2025 across 73 reported records.
Medtronic, Inc. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,277.47 | 24.5% | 14 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $833.68 | 16.0% | 7 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $634.61 | 12.2% | 7 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $399.84 | 7.7% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $318.98 | 6.1% | 11 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $287.82 | 5.5% | 3 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $286.89 | 5.5% | 10 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $151.43 | 2.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $148.98 | 2.9% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $143.08 | 2.7% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $136.29 | 2.6% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $129.63 | 2.5% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 2.4% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $107.03 | 2.0% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $100.00 | 1.9% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $54.43 | 1.0% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $26.56 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.52 | 0.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.64 | 0.3% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $15.26 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,216.14 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $753.11 | 10 | 2025 |
Source payment records
|
|||||
| MANTA Normalized: manta |
Device | Teleflex LLC | $566.67 | 4 | 2025 |
Source payment records
|
|||||
| CARDIOBLATE Normalized: cardioblate |
Device | Medtronic, Inc. | $268.45 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $255.91 | 2 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $239.63 | 2 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $191.75 | 2 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $151.43 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $136.29 | 1 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $129.63 | 1 | 2025 |
Source payment records
|
|||||
| ROSEN Normalized: rosen |
Device | Cook Medical LLC | $129.37 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Laser service and other Normalized: laser service and other |
Device | Philips North America LLC | $107.46 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $107.03 | 1 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $103.50 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $102.80 | 8 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $100.63 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $71.14 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $71.02 | 2 | 2025 |
Source payment records
|
|||||
| General - CRM_CRM Normalized: general crm crm |
Device | Boston Scientific Corporation | $59.37 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $54.43 | 3 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $45.48 | 1 | 2025 |
Source payment records
|
|||||
| CDS broad portfolio offering Normalized: cds broad portfolio offering |
Device | Boston Scientific Corporation | $41.87 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $41.32 | 3 | 2025 |
Source payment records
|
|||||
| ZOOM Wireless Transmitter Normalized: zoom wireless transmitter |
Device | Boston Scientific Corporation | $36.52 | 1 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $36.37 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $32.39 | 1 | 2025 |
Source payment records
|
|||||
| ARROW Normalized: arrow |
Device | Teleflex LLC | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| PERFORMER Normalized: performer |
Device | Cook Medical LLC | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,216.14 · 73 records | Medtronic, Inc. | ACCOLADE SR, ARROW, AURYON LASER SYSTEM 100-120 VAC, AVEIR, Assure WCD, Barostim Neo System, CARDIOBLATE, CARDIVA VASCADE 6/7F VCS, CDS - MCT/CEM Monitoring, CDS broad portfolio offering, COREVALVE EVOLUT R, DRAGONFLY OPSTAR, EMBLEM MRI S-ICD, GUIDELINER, General - Brady, General - CRM_CRM, IGT Devices Undivided, IV Other, Indigo System, LEQVIO, Laser service and other, LifeVest, MANTA, METACROSS OTW, MYNX CONTROL VENOUS, PERFORMER, Paradise Ultrasound Renal Denervation System, ROSEN, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VYNDAQEL, ZOOM Wireless Transmitter | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error